These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6334489)

  • 1. [Substrate specificity of the beta-lactamases found in a number of clinical strains of gram-negative bacteria].
    Sazykin AIu; Navashin SM
    Antibiotiki; 1984 Sep; 29(9):657-61. PubMed ID: 6334489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics of the substrate specificity of the crude endogenous beta-lactamases of gram-negative bacteria].
    Bibikova MV; Ivanitskaia LP; Nikishina VG; Kuznetsova SM
    Antibiotiki; 1983 Aug; 28(8):566-73. PubMed ID: 6416154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of beta-lactamases.
    Bauernfeind A
    Rev Infect Dis; 1986; 8 Suppl 5():S470-81. PubMed ID: 3541132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of AmpC beta-lactamases in Gram-negative bacteria isolated from urine].
    Cernohorská L; Andrysík T
    Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):141-6. PubMed ID: 19069027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
    Szabó D; Barcs I; Rozgonyi F
    Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining extended-spectrum beta-lactamases: balancing science and clinical need.
    Giske CG; Sundsfjord AS; Kahlmeter G; Woodford N; Nordmann P; Paterson DL; Cantón R; Walsh TR
    J Antimicrob Chemother; 2009 Jan; 63(1):1-4. PubMed ID: 18957393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta-lactamases with a wide substrate spectrum in gram negative strictly anaerobic rods].
    Rokosz A; Sawicka-Grzelak A; Kot K; Pituch H; Meisel-Mikołajczyk F; Luczak M
    Med Dosw Mikrobiol; 2000; 52(2):129-37. PubMed ID: 11107787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
    Helfand MS; Bonomo RA
    Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining an extended-spectrum beta-lactamase.
    Livermore DM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of beta-lactamase types of clinical strains of bacteria using a modified microiodometric method].
    Sazykin AIu; Krylov AS; Vakulenko SB; Abadzhieva AN; Nikishina VG
    Antibiotiki; 1984 Jun; 29(6):413-7. PubMed ID: 6433785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the presence of different broad-spectrum beta-lactamases among clinical isolates of Enterobacteriacae.
    Nagy E; Pragai Z; Kóczián Z; Hajdú E; Fodor E
    Acta Microbiol Immunol Hung; 1998; 45(3-4):433-46. PubMed ID: 9873949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-lactamases: a new twist to an old problem.
    Nichols WW
    Microbiol Sci; 1987 May; 4(5):147-8. PubMed ID: 3153189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.